Takaya Mitsuyoshi

Wakayama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Acute development of EBV+ T-cell lymphoproliferative disorder after treatment with rituximab for follicular lymphoma.

Acute development of EBV+ T-cell lymphoproliferative disorder after treatment with rituximab for follicular lymphoma.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: July 07, 2026

Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.

Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.

Journal: Journal for immunotherapy of cancer

Published: April 28, 2026

Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b

Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.

Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.

Journal: Leukemia & lymphoma

Published: December 25, 2025

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Journal: Internal medicine (Tokyo, Japan)

Published: October 29, 2025

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

Journal: Cell reports. Medicine

Published: April 18, 2025

Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry.

Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry.

Journal: Transplantation and cellular therapy

Published: March 26, 2024

HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML.

HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML.

Journal: EJHaem

Published: January 03, 2024

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.

Journal: Blood advances

Published: March 01, 2022

Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.

Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.

Journal: Blood advances

Published: April 06, 2020

Autologous peripheral blood stem cell transplantation for treating primary central nervous system lymphoma: a single-center retrospective study

Autologous peripheral blood stem cell transplantation for treating primary central nervous system lymphoma: a single-center retrospective study

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 09, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026